High-risk prostate cancer represents a pretentious clinical problem since a significant number of its patients will relapse and progress after radical prostatectomy.
Neoadjuvant chemotherapy may be valuable since its efficacy in hormone-resistant prostate cancer has been established. In this paper, we report studies of neoadjuvant chemotherapies that have been used in high-risk patients prior to radical prostatectomy. Even though the results regarding the prognostic surrogates are not significant, the effects on clinical and pathological outcomes are promising, while toxicity in most of the studies is in the expected field.
Written by:
Sfoungaristos S, Kourmpetis V, Fokaefs E, Perimenis P. Are you the author?
Department of Urology, Patras University Hospital, 26500 Patras, Greece.
Reference: Chemother Res Pract. 2013;2013:386809.
doi: 10.1155/2013/386809
PubMed Abstract
PMID: 23509625
UroToday.com Prostate Cancer Section
